SBIR/STTR Research Award
SBIR PHASE 1 TOPIC 43
Award amount
$149,440Program and phase
SBIR · Phase IAward year
2011Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Aphios Corporation
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- HDE2J1H521A7
- Solicitation number
- Not reported
- Topic code
- NHLBI
Research abstract
The contractor will identify methodologies for broad spectrum inactivation of pathogens in red blood cell concentrates(RBCC). RBCCs are the main components of blood used in transfusion medicine, yet currently there are no FDAapproved methods for broad spectrum pathogen inactivation for RBCCs; instead, the risk of transfusion associatedpathogen transmission is reduced by screening the transfused blood for specific pathogens. Solvent-detergentmethod, currently approved by FDA for plasma, is active against only enveloped viruses and cannot be used forRBCCs since the RBCCs have a functional plasma membrane. The use of photodynamic compounds such aspsoralens and methylene blue in conjunction with UV light is approved for plasma and platelets in several Europeancountries but the lack of transparency of RBCCs to UV light can pose special challenges to successful and consistentpathogen inactivation in that system.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Botanical Drug for Chemotherapy Induced Nausea and Vomiting
- Development of a Novel Alzheimer's Disease Therapeutic
- Combination Therapeutic for Chronic Opioid Use Disorder Relapse
- Double-Encapsulated mRNA Vaccine for COVID-19
- CFI Pathogen Inactivation of Human Plasma Units
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY
- Head Up CPR and Aortic Occlusion to Improve Survival after Refractory Cardiac Arrest
- Free-Breathing Dynamic Cardiopulmonary Function Imaging System to use with Xenon MRI
- The Next Wave of Asthma Therapeutics
- Bearingless flux reversal motor for neonatal and pediatric extracorporeal life support applications
Research funding history
44 SBIR/STTR records share this UEI (1994–2025). Reported award amounts total $17,170,079. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, National Science Foundation, Department of Defense